![](/%5E%5Ecdi={43513A8D-0012-473A-A5A1-570018B04076}%5Ehash=/-/media/project/qiagen/qiagen-home/content-worlds/tb-management/risk-groups/biologics-rg/s_9297_clinical_patient_gi954160202_1280x720.jpg)
Featured resources
Reduce the risk of future complications
In addition to screening for TB at the onset of immunotherapy, retesting every 1–2 years for patients who have a new or recurring risk factor should be considered. Risk factors include living in or extended travel to an endemic country, TB exposure, or employment in a healthcare or congregate setting. Risk factors such as smoking, substance use disorders, diabetes, etc. should also be considered.
Choose modern testing for your at-risk patients
Reduce the risk of TB with QuantiFERON-TB Gold Plus
References:
- Lobue, P. and Menzies, D. Treatment of latent tuberculosis infection: An update. Respirology. 2010;15: 603-622.
- Lewinsohn DM, et al. Official ATS/IDSA/CDC clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;111-115.
- US CDC. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection — United States, 2010. MMWR 2010; 59, RR-5.
- World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. 2020.
- Fragoulis, GE, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2022;0:1–12.
- Diel, R, et al. Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie. 2021;75: 293–303
- NSTC/NTCA. Testing and treatment of latent tuberculosis infection in the United States: clinical recommendations. February 2021.
- Anastasopoulou, A, et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunotherapy Cancer 2019;7:239.
- Lin, C, et al. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review. Front. Immunol. 2023;14:1162190.